More recently, in the phase III IPATential150 trial, ipatasertib achieved significantly superior radiographic progression–free survival and antitumor activity in combination with abiraterone as first-line treatment for mCRPC in patients with PTEN loss by IHC42, further demonstrating the clinical relevance for AKT inhibitors in PTEN-null prostate cancers. Here, PTEN is linked to prostate carcinoma.